Search

Your search keyword '"Paydas, Saime"' showing total 326 results
Start Over Author "Paydas, Saime"
326 results on '"Paydas, Saime"'

3. Characteristics of primary glomerular diseases patients with hematuria in Turkey: the data from TSN-GOLD Working Group

Author

Sumnu, Abdullah, Turkmen, Kultigin, Cebeci, Egemen, Turkmen, Aydin, Eren, Necmi, Seyahi, Nurhan, Oruc, Aysegul, Dede, Fatih, Derici, Ülver, Basturk, Taner, Şahin, Garip, Sipahioglu, Murat, Sahin, Gulizar Manga, Tatar, Erhan, Dursun, Belda, Sipahi, Savas, Yılmaz, Mürvet, Suleymanlar, Gultekin, Ulu, Sena, Gungor, Ozkan, Kutlay, Sim, Bahçebaşı, Zerrin Bicik, Sahin, İdris, Kurultak, Ilhan, Sevinc, Can, Yilmaz, Zulfikar, Kazancioglu, Rumeyza Turan, Cavdar, Caner, Candan, Ferhan, Aydin, Zeki, Oygar, Deren, Gul, Bulent, Altun, Bulent, Paydas, Saime, Uzun, Sami, Istemihan, Zulal, Ergul, Metin, Dincer, Mevlut Tamer, Gullulu, Mustafa, Piskinpasa, Serhan, Akcay, Omer Faruk, Unsal, Abdulkadir, Koyuncu, Sumeyra, Gok, Mahmut, and Ozturk, Savas

Published
2021
Full Text
View/download PDF

9. Epidemiological features of primary glomerular disease in Turkey: a multicenter study by the Turkish Society of Nephrology Glomerular Diseases Working Group

Author

Turkmen, Aydin, Sumnu, Abdullah, Cebeci, Egemen, Yazici, Halil, Eren, Necmi, Seyahi, Nurhan, Dilek, Kamil, Dede, Fatih, Derici, Ulver, Unsal, Abdulkadir, Sahin, Garip, Sipahioglu, Murat, Gok, Mahmut, Tatar, Erhan, Dursun, Belda, Sipahi, Savas, Yilmaz, Murvet, Suleymanlar, Gultekin, Ulu, Sena, Gungor, Ozkan, Kutlay, Sim, Bahcebasi, Zerrin Bicik, Sahin, Idris, Kurultak, Ilhan, Turkmen, Kultigin, Yilmaz, Zulfikar, Kazancioglu, Rumeyza Turan, Cavdar, Caner, Candan, Ferhan, Aydin, Zeki, Oygar, Duriye Deren, Gul, Cuma Bulent, Arici, Mustafa, Paydas, Saime, Taymez, Dilek Guven, Kucuk, Mehmet, Trablus, Sinan, Turgutalp, Kenan, Koc, Leyla, Sezer, Siren, Duranay, Murat, Bardak, Simge, Altintepe, Lutfullah, Arikan, Izzet Hakki, Azak, Alper, Odabas, Ali Riza, Sahin, Gulizar Manga, and Ozturk, Savas

Published
2020
Full Text
View/download PDF

17. Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial

Author

Roger, Simon D., Gaillard, Carlo A., Bock, Andreas H., Carrera, Fernando, Eckardt, Kai-Uwe, Van Wyck, David B., Cronin, Maureen, Meier, Yvonne, Larroque, Sylvain, Macdougall, Iain C., Gilles, Alastair, Faull, Randall, Toussaint, Nigel D., McMahon, Lawrence, Suranyi, Michael, Mudge, David, Hutchison, Brian, Irish, Ashley, Kerr, Peter, Kulkarni, Hemant, Elder, Grahame, Jardine, Margaret, Lhotta, Karl, Mayer, Gert, Vanholder, Raymond, Maes, Bart Dirk, Evenepoel, Pieter, Debelle, Frédéric, Jadoul, Michel, Dratwa, Max, Macel, Igor, Dunaj, Milan, Kvapil, Milan, Bucek, Petr, Rehorova, Jitka, Hruby, Ales, Honová, Václava, Malanova, Lada, Lucak, Martin, Lecian, Dalibor, Jirovec, Martin, Vlasak, Jiri, Rychlik, Ivan, Surel, Stanislav, Kamper, Anne-Lise, Ostergaard, Ove, Steffensen, Gudrun K, Chenine, Leila, Choukroun, Gabrial, Zaoui, Philippe, Wanner, Christoph, Backs, Wolfgang, Kraatz, Uwe, Dellanna, Frank, Busch, Klaus, Marsen, Tobias, Seeger, Wolfgang, Woitas, Rainer, Obermueller, Nicholas, Haak, Thomas, Lueders, Stephan, Pistrosch, Frank, Mueller, Eckhard, Mertens, Peter R., Sutermer, Werner, Grebe, Scott-Oliver, Hafezi-Rachti, Syrus, Roeser, Silke, Tsakiris, Dimitrios, Memmos, Dimitrios, Vlachakos, Demetrios, Vargemezis, Vassilis, Stefanidis, Ioannis, Syrganis, Christos, Alivanis, Polichronis, Papadakis, Ioannis, Papagalanis, Nickolaos, Andrikos, Aimilios, Goumenos, Dimitrios, Siamopoulos, Kostas, Gouva, Charikelia, Papadakis, Gabriel, Boletis, Ioannis, Tsimnadi-Spanoudaki, Myrsini, Stamatiades, Dimitrios, Stamatelou, Kyriaki, Moutafis, Spyridon, Locatelli, Francesco, Santoro, Antonio, Quarello, Francesco, Remuzzi, Giuseppe, Coppola, Salvatore, Mortellaro, Rosella Ferraro, Icardi, Andrea, Colussi, Giacomo, Grotta, Franco Della, Lombardi, Luigi, Gallieni, Maurizio, Villa, Giuseppe, Grandaliano, Giuseppe, Gaillard, Carlo, Huisman, Sebastiaan, Barendregt, Jos, Smak Gregoor, Peter JH, Oien, Cecilia, Rutkowski, Boleslaw, Malecki, Robert, Nowicki, Michal, Rutkowski, Przemyslaw, Marczewski, Kryzsztof, Mysliwiec, Michal, Sydor, Antoni, Rysz, Jacek, Rydzewski, Andrzej, Klinger, Marian, Wnuk, Rafal, Kozminski, Piotr, Nocon, Anna, Ciechanowski, Kazimierz, Correia, Pedro, Neves, Fernando, Barata, José, Mircescu, Gabriel, Voiculescu, Mihai, Gluhovschi, Gheorghe, Mota, Eugen, De Francisco, Angel Luís Martín, Torre, Alberto, Herreros, Alba, Luño, José, Gruss, E., Martins, Judith, Vallés, Marti, Pascual, Julio, Bárány, Peter, Ambuehl, Patrice M., Erturk, Sehsuvar, Arici, Mustafa, Paydas, Saime, Soypacaci, Zeki, Camsari, Taner, Ustundag, Sedat, Thomas, Mark E., DʼSouza, Richard J., Taylor, Jo E., Pritchard, Nicholas R., Jeffery, Robin, Riley, Stephen G., Bhatnagar, Deepak, Bhandari, Sunil, Reaich, David, Stevens, Paul E., El Kossi, Mohsen, Roe, Simon, Camilleri, Brian, Ahmed, Aimun, Khwaja, Arif, Thompson, Barbara, Banerjee, Debasish, Nicholas, Johann, Hutchison, Alastair, and Borrows, Richard

Published
2017
Full Text
View/download PDF

18. The effect of subclinic thyroid pathologies on erythropoietine dose in hemodialysis patients.

Author

Onan, Engin, Yasar, Mehmet, Soysal, Busra, and Paydas, Saime

Subjects
HEMODIALYSIS patients, HYPOTHYROIDISM, THYROID gland, ERYTHROPOIETIN, PATHOLOGY
Abstract

Purpose: The effect of subclinical thyroid pathologies on erythropoietin (EPO) treatment has not been well defined. The aim of the study is to compare the frequency and dose of EPO administration in patients with subclinical thyroid pathology and euthyroid hemodialysis patients. Methods: A cross‐sectional and retrospective study was conducted with 210 patients. Special conditions were excluded, a total of 191 patients were included. Patients were divided into three groups. Results: The incidences of subclinical hypothyroidism, subclinical hyperthyroidism and euthyroidism were 10.5%, 3.1%, and 86.4%, respectively. Statistically significant difference was found between subclinical hypothyroid and euthyroid patients in terms of the number of patients using EPO (p = 0.0207), monthly total EPO doses (p = 0.003), and total monthly EPO doses per weight (p = 0.001). Conclusion: The EPO dose required to achieve similar hemoglobin levels in hemodialysis patients was significantly higher in subclinical hypothyroid patients than in euthyroid patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. The Effect of Pentoxifylline Treatment on Diabetic Nephropathy Progression

Author

ONAN, Engin, PAYDAS, Saime, BALAL, Mustafa, TAKTAKOĞLU, Onur, and KARA, Ertan

Subjects
Diabetik nefropati, pentoksifilin, proteinüri, Pentoxifylline, Diabetic Nephropathy, proteinuria, Health Care Sciences and Services, Sağlık Bilimleri ve Hizmetleri
Abstract

ÖzetAmaç: Diabetik nefropati (DN) son dönem böbrek yetersizliğinin önemli bir nedenidir. Vasküler hastalıklarda kullanılan ve anti-inflamatuar özellikleri olan pentoksifilinin diyabetik nefropatide olumlu etkileri olabileceği öne sürülmüştür. Bu çalışmada DN nedeni ile takipte olan ve pentoksifilin kullanan hastaların tedavi öncesi ve sonrası dönemdeki böbrek fonksiyonları ve proteinürileri değerlendirilmiştir. Gereç ve Yöntemler: Kliniğimizde takipte olup pentoksifilin (1200 mg/gün) tedavisi alan 36 diabetik nefropati hastası retrospektif olarak tarandı. Tedavi başlanmadan önceki 3. ve 6. ay; pentoksifilin tedavisinin 3., 6., 9. ve 12. aylardaki günlük proteinüri miktarı ve eGFR (estimated glomerular filtration rate, tahmini glomerüler filtrasyon hızı) değerleri kayıt edildi.Bulgular: Çalışmaya alınan 36 hastanın ortalama yaşı 51.9±12.3 yıl, 12’si erkek ve 16’sı Anjiotensin dönüştürücü enzim (Angiotensin converting enzyme inhibitor, ACEİ) ya da Anjiotensin reseptör blokeri (Angiotensin receptor blocker, ARB) kullanıyordu. Pentoksifilini 23 hasta ≤6 ay (A grubu) 13 hasta >6 ay (B grubu) süre kullanmıştı. Proteinüri miktarı ve eGFR kaybı yönünden her iki grupta anlamlı farklılık saptanmadı. Sonuç: Çalışmamızda diabetik nefropatili hastalarda 1 yıllık takip sırasında pentoksifilin tedavisinin proteinüri miktarı ve eGFR kaybına etkisi saptanamamıştır., Objective: Diabetic nephropathy (DN) is an important cause of end stage renal disease. It has been suggested that pentoxifylline, which is used for the treatment of vascular diseases, has anti-inflammatory properties and may have positive effects on diabetic nephropathy. In this study, we aimed to investigate the effect of pentoxifylline treatment on renal functions and proteinuria levels in patients with DN.Material and Methods: Thirty-six DN patients treated with 1200 mg/day pentoxifylline were screened retrospectively. Twenty-four-hour proteinuria and estimated glomerular filtration rate (eGFR) values were recorded at 3rd and 6th months before starting treatment and at 3rd, 6th and 12th months of pentoxifylline treatment.Results: The average age was 51.9±12.3 years. In this patient cohort, 12 were male and 16 were using angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blockers (ARB). Twenty-three patients used pentoxifylline for less than 6 months (group A) and 13 patients used it for more than 6 months (group B). There was no difference between groups A and B regarding the amount of 24-hour proteinuria (Group A: 3.76±2.49 g/day, Group B: 4.72±3.20 g/day, p=0.423) and loss of eGFR (Group A: 37.98±31.2 ml/min, Group B: 34.00±29.99 ml/min, p=0.846).Conclusion: In this study, the effect of pentoxifylline on proteinuria and eGFR loss was not observed in patients with diabetic nephropathy during 1-year follow-up.

Published
2022

29. International Study on Sagliker Syndrome and Uglifying Human Face Appearence in Severe and Late Secondary Hyperparathyroidism in Chronic Kidney Disease Patients

Author

Sagliker, Yahya, Acharya, Vidya, Ling, Zhang, Golea, Ovidia, Sabry, Alaa, Eyupoglu, Kamil, Ookalkar, Dhananjay S., Tapiawala, Shruti, Durugkar, Santosh, Khetan, Prakash, Capusa, Cristina, Univar, Ramazan, Yildiz, Ismail, Cengiz, Kuddisi, Bali, Musa, Ozkaynak, Piril Sagliker, Sagliker, Hasan Sabit, Paylar, Nuray, Adam, Siddik Momin, Balal, Mustafa, Paydas, Saime, Demirhan, Osman, Tasdemir, Deniz, Maiz, Hedi Ben, Redulescu, Dana, Garneata, Liliana, Mircescu, Gabriel, Hong-Liang, Rui, Lun, Lide, Yildizer, Kasim, Emir, Idris, Yuksekgonul, Musa, Yenicerioglu, Yavuz, Akar, Harun, Sagliker, Cemal, Esenturk, Mustafa, and Kiralp, Necati

Published
2008
Full Text
View/download PDF

35. Hepatit-B ve C enfeksiyonlarının böbrek transplatasyonunda graft ve karaciğer fonksiyonlarına etkisi: Türkiye'den tek merkez deneyimi

Author

KARAER BÜBERCİ, Refika and PAYDAS, Saime

Subjects
Medicine, Böbrek nakli,Hepatit B ve C enfeksiyonları,Son dönem böbrek yetmezliği, Tıp
Abstract

AMAÇ: İmmünsüpresif tedaviden dolayı hepatit-B veya C enfeksiyonlarının böbrek nakilli hastalarda graft ve hasta sağ kalımına olumsuz etki ettiği konusu tartışmalıdır. Çalışmamızın amacı böbrek nakilli hastalarda hepatit-B ve C enfeksiyonlarının hasta ve graft üzerine etkilerini değerlendirmektir.GEREÇ VE YÖNTEMLER: Çalışmaya 66 böbrek nakil hastası alındı. Anti-HCVpozitif beş hasta ve Hbs-Ag pozitif dokuz hasta viral hepatit grubunu oluşturdu. Geri kalan 52 hasta (anti-HCV, Hbs-Ag negatif) viral hepatiti olmayan grubu oluşturdu. Hastane kayıtları retrospektif olarak tarandı. Nakil sonrası ilk üç yıllık AST, ALT, albumin, hesaplanmış glomerüler filtrasyon hızı (hGFH) not edildi.BULGULAR: Transplant sonrası takip süresi ortalama olarak viral hepatit grubunda 62,4 ±48,2 ay viral hepatiti olmayan grupta 35,3±15,7 ay idi. Cinsiyet, donör tipi, yaş, transplant sonrası nakil süresi açısından iki grup arasında anlamlı fark yoktu. Sadece nakil öncesi diyaliz süresi hepatit grubunda anlamlı daha uzundu. hGFH (sırasıyla viral hepatit olmayan grupta 73,5±22,7, 69,3±23, 63,5±22,1 mL/dk, viral hepatit grubunda 78,8±15,7, 70,6±12,5, 61,2±13,1 mL/dk), AST, ALT, albumin birinci, ikinci, üçüncü yıllarda iki grupta benzerdi Ancak üçüncü yılın sonundaki hGFH'deki düşüş hızı ve AST/ALT’deki artış hızı viral hepatit grubunda istatistiksel olarak anlamlı daha fazlaydı. hGFH'deki düşüşün kadınlarda daha hızlı olduğu tespit edilirken, kolerasyon analizinde yaş ve nakil öncesi diyaliz süresinin hGFH'deki düşüşe etkisi bulunmadı.SONUÇ: Üç yıllık takipte hGFH ve AST/ALT değerleri iki grupta benzerdi. Hiçbir hastada graft kaybı, karaciğer yetmezliği, ölüm gelişmedi. Günümüzde hepatit-C enfeksiyonu için başarılı tedaviler uygulanmakla birlikte anti viral tedavi uygulanmamış hepatiti pozitif olan son dönem böbrek yetmezlikli hastalarda böbrek nakli, iyi bir değerlendirme sonrası güvenli ve etkili bir tedavi seçeneği olarak kabul edilebilir.

Published
2020

36. THE EPIDEMIOLOGICAL FEATURES OF PIRMARY GLOMERULAR DISEASES IN TURKEY: THE MULTICENTER STUDY OF TURKISH SOCIETY OF NEPHROLOGY GLOMERULAR DISEASES (TSN-GOLD) WORKING GROUP

Author

Turkmen, Aydin, Sumnu, Abdullah, Cebeci, Egemen, Yazici, Halil, Eren, Necmi, Seyahi, Nurhan, Dilek, Kamil, Dede, Fatih, Derici, Ulver, Unsal, Abdulkadir, Sahin, Garip, Sipahioglu, Murat, Gok, Mahmut, Tatar, Erhan, Dursun, Belda, Sipahi, Savas, Yilmaz, Murvet, Suleymanlar, Gultekin, Ulu, Memnune, Gungor, Ozkan, Kutlay, Sim, Bahcebasi, Zerrin, Sahin, Idris, Kurultak, Ilhan, Kultigin Turkmen, Yilmaz, Zulfikar, Kazancioglu, Rumeyza, Cavdar, Caner, Candan, Ferhan, Aydin, Zeki, Oygar, Deren, Gul, Cuma, Arici, Mustafa, Paydas, Saime, Taymez, Dilek, Kucuk, Mehmet, Trablus, Sinan, Turgutalp, Kenan, Koc, Leyla, Sezer, Siren, Duranay, Murat, Bardak, Simge, Altintepe, Luftullah, Arikan, Izzet, Azak, Alper, Odabas, Ali, Sahin, Gulizar, Ozturk, Savas, and KAZANCIOĞLU, Rümeyza

Subjects
THE MULTICENTER STUDY OF TURKISH SOCIETY OF NEPHROLOGY GLOMERULAR DISEASES (TSN-GOLD) WORKING GROUP-, 57th ERA-EDTA Congress, ELECTR NETWORK, 6 - 09 Haziran 2020, cilt.35, ss.811 [Turkmen A., Sumnu A., Cebeci E., Yazici H., Eren N., Seyahi N., Dilek K., Dede F., Derici U., Unsal A., et al., -THE EPIDEMIOLOGICAL FEATURES OF PIRMARY GLOMERULAR DISEASES IN TURKEY]
Published
2020

45. Cephalometric Evaluation of Patients With Sagliker Syndrome: Uglifying Human Face Appearance in Severe and Late Secondary Hyperparathyroidism in Chronic Renal Failure Patients

Author

Uzel, Asli, Uzel, Ilter, Sagliker, Yahya, Yildiz, Ismail, Halvaci, Ilker, Paylar, Nuray, Ocal, Fatih, Balal, Mustafa, Ozkaynak, Piril Sagliker, Paydas, Saime, Sagliker, Cemal, Sagliker, Hasan Sabit, Kiralp, Necati, Adam, Sidik Momin, Esenturk, Mustafa, Gocmez, Erdal, Taskapan, Hulya, Yuksekgonul, Musa, Emir, Idris, Guler, Turgay, Yakar, Hasan, Sekin, Oktay, Kayali, Erkan, Caliskan, Sihli, Eskiocak, Ali Fuat, Ogruk, Bulent, Guzelyurt, Tahsin, and Kurt, Cemal

Published
2006
Full Text
View/download PDF

46. Neurologic Manifestations in Sagliker Syndrome: Uglifying Human Face Appearance in Severe and Late Secondary Hyperparathyroidism in Chronic Renal Failure Patients

Author

Giray, Semih, Sagliker, Yahya, Yildiz, Ismail, Halvacı, Ilker, Paylar, Nuray, Ocal, Fatih, Balal, Mustafa, Ozkaynak, Piril Sagliker, Paydas, Saime, Sagliker, Cemal, Sagliker, Hasan Sabit, Kıralp, Necati, Adam, Siddik Momin, Esenturk, Mustafa, Gocmez, Erdal, Taskapan, Hulya, Yuksekgonul, Musa, Emir, Idris, Guler, Turgay, Yakar, Hasan, Sekin, Oktay, Kayali, Erkan, Caliskan, Sihli, Eskiocak, Ali Fuat, Ogruk, Bulent, Guzelyurt, Tamer, and Kurt, Cemal

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results